Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

KalVista Pharmaceuticals (KALV) Shares Outstanding (Weighted Average): 2014-2025

Historic Shares Outstanding (Weighted Average) for KalVista Pharmaceuticals (KALV) over the last 12 years, with Apr 2025 value amounting to $49.7 million.

  • KalVista Pharmaceuticals' Shares Outstanding (Weighted Average) rose 17.84% to $49.7 million in Q2 2025 from the same period last year, while for Oct 2024 it was $49.4 million, marking a year-over-year increase of 43.64%. This contributed to the annual value of $49.7 million for FY2025, which is 17.84% up from last year.
  • Per KalVista Pharmaceuticals' latest filing, its Shares Outstanding (Weighted Average) stood at $49.7 million for FY2025, which was up 17.84% from $42.2 million recorded in FY2024.
  • KalVista Pharmaceuticals' 5-year Shares Outstanding (Weighted Average) high stood at $49.7 million for FY2025, and its period low was $24.3 million during FY2021.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $42.2 million (2024), whereas its average is $42.0 million.
  • Data for KalVista Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY surged of 39.48% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows KalVista Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $24.3 million in 2021, then climbed by 0.97% to $24.5 million in 2022, then spiked by 39.48% to $34.2 million in 2023, then increased by 23.24% to $42.2 million in 2024, then rose by 17.84% to $49.7 million in 2025.